Despite the variety of different targeted therapies for ccRCC (e.g., anti‐vascular endothelial growth factor receptor therapy, also known as anti‐VEGFR therapy, and mTOR pathway‐targeted therapy), there are currently no phase III clinical trial data on non‐ccRCCs.12 The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.